A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party telehealth prescribers to get their hands on these medications ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors.

When Trova Wine and Market shut its doors last month after nearly five years in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like Ozempic.

The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control. The stock has ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.

Please provide your email address to receive an email when new articles are posted on . The risk for thyroid cancer within the first year of follow-up was higher with GLP-1 therapy vs. other ...

Working with a weight management program can help sustain the use of GLP-1 therapies and address potential side effects. Patient education and expectation management are crucial for maximizing ...

Of the patients, 215,970 initiated treatment with GLP-1 RAs; 159,465 started sulfonylureas, 117,989 dipeptidyl peptidase 4 inhibitors, and 258,614 were initiated on sodium-glucose cotransporter-2 ...